AR062659A1 - Composicion de liberacion sostenida de levodopa y metodo para su uso - Google Patents
Composicion de liberacion sostenida de levodopa y metodo para su usoInfo
- Publication number
- AR062659A1 AR062659A1 ARP070103916A ARP070103916A AR062659A1 AR 062659 A1 AR062659 A1 AR 062659A1 AR P070103916 A ARP070103916 A AR P070103916A AR P070103916 A ARP070103916 A AR P070103916A AR 062659 A1 AR062659 A1 AR 062659A1
- Authority
- AR
- Argentina
- Prior art keywords
- levodopa
- subject
- composition
- interval
- hours
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 9
- 229960004502 levodopa Drugs 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000001095 motoneuron effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones farmacéuticas que comprende levodopa y que, cuando se administra en una dosis unitaria de levodopa de alrededor de 100 hasta alrededor de 500 mg con un intervalo entre tomas de alrededor de 6 hasta alrededor de 24 horas, exhibe un período de liberacion suficientemente prolongado y un tiempo de residencia suficientemente prolongado en el tracto gastrointestinal alto para proporcional una concentracion mínima de levodopa en el plasma del sujeto que no es inferior a una concentracion umbral mínima por debajo de la cual se observan en el sujeto efectos motores adversos. También se proporciona un método para tratar la enfermedad de Parkinson en un sujeto, que comprende administrar por vía oral dicha composicion al sujeto en una dosis unitaria de levodopa de alrededor de 50 hasta alrededor de 1000 mg con un intervalo entre tomas de alrededor de 3 hasta alrededor de 24 horas. Reivindicacion 1: Una composicion farmacéutica que se puede administrar por vía oral y que comprende levodopa y al menos un excipiente adecuado para uso farmacéutico, caracterizada porque la composicion, cuando se administra por vía oral en una dosis unitaria de levodopa de alrededor de 100 hasta alrededor de 50 mg a un sujeto humano con un intervalo entre tomas de alrededor de 6 hasta alrededor de 24 horas, exhibe (a) un período de liberacion de levodopa suficientemente prolongado y (b) un tiempo de resistencia en el tracto gastrointestinal alto del sujeto suficientemente prolongado para proporcionar una concentracion mínima de levodopa en el plasma del sujeto que no es inferior a una concentracion umbral mínima de alrededor de 300 ng/ml.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82498506P | 2006-09-08 | 2006-09-08 | |
| US82827606P | 2006-10-05 | 2006-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062659A1 true AR062659A1 (es) | 2008-11-26 |
Family
ID=39157983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103916A AR062659A1 (es) | 2006-09-08 | 2007-09-05 | Composicion de liberacion sostenida de levodopa y metodo para su uso |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080139655A1 (es) |
| AR (1) | AR062659A1 (es) |
| CL (1) | CL2007002574A1 (es) |
| PE (1) | PE20080669A1 (es) |
| WO (1) | WO2008030830A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101687781B1 (ko) | 2008-08-15 | 2016-12-20 | 데포메드 인코퍼레이티드 | Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물 |
| US10022320B2 (en) | 2014-03-13 | 2018-07-17 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| ES2897024T3 (es) * | 2017-03-01 | 2022-02-28 | Arena Pharm Inc | Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas |
| CN109439645B (zh) * | 2018-10-31 | 2022-07-19 | 武汉工程大学 | 利用锐孔法制备解磷微生物缓释海藻酸钠微球的方法 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| WO2022005926A1 (en) * | 2020-06-30 | 2022-01-06 | Imbria Pharmaceuticals, Inc. | Modified release formulations of modified forms of trimetazidine |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| KR20030013460A (ko) * | 2000-06-23 | 2003-02-14 | 테바 파마슈티컬 인더스트리즈 리미티드 | 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형 |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| WO2004032906A1 (en) * | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
-
2007
- 2007-09-05 AR ARP070103916A patent/AR062659A1/es unknown
- 2007-09-05 WO PCT/US2007/077572 patent/WO2008030830A2/en active Search and Examination
- 2007-09-05 PE PE2007001186A patent/PE20080669A1/es not_active Application Discontinuation
- 2007-09-05 US US11/850,063 patent/US20080139655A1/en not_active Abandoned
- 2007-09-05 CL CL200702574A patent/CL2007002574A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080139655A1 (en) | 2008-06-12 |
| WO2008030830A3 (en) | 2008-05-29 |
| CL2007002574A1 (es) | 2008-05-23 |
| WO2008030830A2 (en) | 2008-03-13 |
| PE20080669A1 (es) | 2008-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
| PE20060588A1 (es) | Composiciones farmaceuticas que contienen flibanserina | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| CA3094580A1 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |